Japan Launches Groundbreaking Artificial Blood Trial

Researchers at Nara Medical University in Japan have initiated a clinical trial to develop universal artificial blood, addressing global blood shortages. This artificial blood, derived from hemoglobin extracted from expired donor blood, is designed to be virus-free, compatible with any blood type, and has a shelf life exceeding a year at room temperature.
In March, the trial administered 100 to 400 milliliters of artificial blood to 16 healthy volunteers. Professor Ash Toye of the University of Bristol highlighted the potential benefits, such as eliminating blood type mismatches and enabling access to areas with limited medical infrastructure. However, he also noted challenges, including reliance on human hemoglobin and the need for further testing to ensure safety and efficacy.
The researchers aim to expand trials and seek approval from Japan's Ministry of Health for mass adoption. If successful, this innovation could revolutionize emergency medicine, offering a reliable and scalable blood supply for critical situations worldwide.

Published: 6/3/2025